Category: Judicial

The federal judge considering drug manufacturer Sanofi’s motion for protection from 340B dispute resolution proceedings asked the company and the federal government last Wednesday to brief her on a different federal judge’s order the day before granting drug company Eli

Ryan White Clinics for 340B Access (RWC-340B) and the federal government have a deadline today to report to a federal judge about whether to continue the stay in the group’s suit to force the government to act against drug manufacturers

A federal judge’s decision to temporarily shield drug manufacturer Eli Lilly from the 340B program’s administrative dispute resolution (ADR) process could cause the government to issue 340B ADR regulations all over again, health care attorneys say.

U.S. District Judge Sarah

In a decision that could have significant implications for 340B stakeholders, a federal district judge in Indianapolis today granted drug manufacturer Eli Lilly’s motion for a preliminary injunction stopping the U.S. Health and Human Services Department from implementing or enforcing

Drug manufacturer Sanofi on Monday struck back at the U.S. Justice Department (DOJ) for opposing its Feb. 2 motion in a federal lawsuit requesting an injunction against the 340B program’s new administrative dispute resolution (ADR) process.

“The government is eager

Hospital groups that recently filed a motion to intervene in opposition to drug manufacturer Eli Lilly’s lawsuit against the federal government over 340B contract pharmacy requirements also are trying to intervene in similar suits against the government by manufacturers AstraZeneca,

The hospital groups that last week lost a federal lawsuit in California to make federal health officials enforce 340B contract pharmacy requirements for drug manufacturers have asked a federal court in Indiana to make them parties in opposition to manufacturer

Thirty-six state and regional hospital associations on Tuesday urged the U.S. Supreme Court to overturn a federal appeals court’s 2-1 July 2020 decision that upheld the nearly 30 percent cut since 2018 in 340B hospitals’ drug reimbursement under the hospital